Cancer originating from germ cells is a special disease, characterized by increased incidence in young men (18–40 years) and extremely good prognosis, even if it is diagnosed in advanced stages. The vast majority of these cancers are originated in the gonads (testicles), while a small percentage of germ cell tumors may appear in midline extragonadal locations that are embryologically developed from the central crest (epiphysis, mediastinum, retro peritoneum).
KeywordsGerm cell tumors Testicular cancer Seminoma Non-seminoma Yolk sac Teratoma Embryonal carcinoma
- 16.de Wit R, Stoter G, Kaye SB et al (1997) Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cooperative Group. J Clin Oncol 15:1837CrossRefGoogle Scholar
- 19.Horwich A, Sleijfer D, Fossa S et al (1997) Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a multi-institutional Medical Research Council/European Organization for Research and Treatment of Cancer trial. J Clin Oncol 15:1844CrossRefGoogle Scholar
- 23.Kaye S, Mead G, Fossa S et al (1998) Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a randomized Medical Research Council/European Organization for Research and Treatment of Cancer Study. J Clin Oncol 16:692CrossRefGoogle Scholar
- 24.Nichols CR, Catalano P, Crawford ED et al (1998) Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors; an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study. J Clin Oncol 16:1287CrossRefGoogle Scholar
- 27.Schmoll H-J, Kollmannsberger C, Metzner JT et al (2003) Long-term results of first-line sequential high-dose VIPchemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group. J Clin Oncol 21:4083CrossRefGoogle Scholar